Form 4: Korro Bio Director Receives Stock Option Grant

Director Timothy R. Pearson was granted 14,677 stock options in Korro Bio, Inc. as part of standard compensation.

Summary

• Director Timothy R. Pearson received a grant of 14,677 stock options on June 10, 2026.
• The options have an exercise price of $10.59 per share.
• The options are set to expire on June 9, 2036.
• The grant is subject to a one-year vesting schedule tied to the next annual meeting or the one-year anniversary of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $10.59 exercise price.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with corporate performance.

Comparison to Industry Standards

• The grant size and vesting terms are consistent with typical director compensation packages for small-cap biotechnology firms.
• The use of a one-year cliff vesting period is standard for board-level equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon future exercise of options.

Next Steps

• Vesting of options on the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Korro Bio, KRRO, Form 4, Insider Trading, Stock Options, Director Compensation